Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease

Abstract

Based on these findings, this research highlights the in-vitro/in-vivo efficacy of nanoformulated BNZ against T. cruzi acute infections in immunosuppressed and non-immunosuppressed mice and provides further evidence for the optimization of dosage regimens to treat Chagas disease.